📣 VC round data is live. Check it out!
- Public Comps
- Meinian Onehealth
Meinian Onehealth Valuation Multiples
Discover Meinian Onehealth's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Global Health, Concentra Group, Option Care Health, Medicover and more.
Meinian Onehealth Overview
About Meinian Onehealth
Meinian Onehealth Healthcare Holdings Co Ltd is engaged in the provision of physical examination and medical services. The firm provides health consultation, and health assessment services among others.
Founded
2004
HQ

Employees
2.1K
Website
Sectors
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trialMeinian Onehealth Financials
Meinian Onehealth reported last 12-month revenue of $2B and EBITDA of $286M.
In the same LTM period, Meinian Onehealth generated $641M in gross profit, $286M in EBITDA, and $50M in net income.
Revenue (LTM)
Meinian Onehealth P&L
In the most recent fiscal year, Meinian Onehealth reported revenue of $2B and EBITDA of $322M.
Meinian Onehealth is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of 21%, and net margin of 3%.
Financial data powered by Morningstar, Inc.
Meinian Onehealth Stock Performance
Meinian Onehealth has current market cap of $3B, and enterprise value of $4B.
Market Cap Evolution
Meinian Onehealth's stock price is $0.84.
Meinian Onehealth share price increased by 0.4% in the last 30 days, and by 12.9% in the last year.
Meinian Onehealth has an EPS (earnings per share) of $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $3B | 0.4% | 0.4% | 2.0% | 12.9% | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMeinian Onehealth Valuation Multiples
Meinian Onehealth trades at 2.4x EV/Revenue multiple, and 13.2x EV/EBITDA.
EV / Revenue (LTM)
Meinian Onehealth Financial Valuation Multiples
As of June 2, 2026, Meinian Onehealth has market cap of $3B and EV of $4B.
Meinian Onehealth has a P/E ratio of 65.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Meinian Onehealth Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Meinian Onehealth Margins & Growth Rates
Meinian Onehealth grew revenue by 4% but EBITDA decreased by 26% in the last fiscal year.
In the most recent fiscal year, Meinian Onehealth reported gross margin of 41%, EBITDA margin of 21%, and net margin of 3%.
Meinian Onehealth Margins
Meinian Onehealth Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Meinian Onehealth Operational KPIs
Meinian Onehealth's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.2M for the same period.
Meinian Onehealth's Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Meinian Onehealth's Rule of X is 24% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Meinian Onehealth Competitors
Meinian Onehealth competitors include Global Health, Concentra Group, Option Care Health, Medicover, Krishna Institute, Asker Healthcare Group, Mouwasat, LifeStance Health, Kpj Healthcare and IKS Health.
Most Meinian Onehealth public comparables operate across Hospitals & Clinics.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 7.1x | 7.0x | 30.9x | 32.8x | |||
| 2.4x | 2.4x | 12.3x | 11.8x | |||
| 0.8x | 0.8x | 9.1x | 9.1x | |||
| 1.8x | 1.7x | 10.9x | 10.4x | |||
| 8.8x | 8.4x | 41.8x | 40.5x | |||
| 2.1x | 2.0x | 17.6x | 16.7x | |||
| 4.2x | 4.0x | 11.9x | 12.0x | |||
| 2.3x | 2.2x | 20.9x | 18.3x | |||
This data is available for Pro users. Sign up to see all Meinian Onehealth competitors and their valuation data. Start Free Trial | ||||||
Meinian Onehealth VC Funding History
Before going public, Meinian Onehealth raised $49M in total equity funding, across 1 round.
Meinian Onehealth Funding Rounds
Acquisitions by Meinian Onehealth
Meinian Onehealth has acquired 1 company to date.
Last acquisition by Meinian Onehealth was on June 14th 2017. Meinian Onehealth acquired Ciming Checkup for $7M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Meinian Onehealth
| Description | Ciming Checkup is a Beijing-based preventive healthcare provider operating China's first dedicated health examination centers since 1993. Services include physical checkups, private physician consultations, digital health tracking, medical referrals, and insurance products under sub-brands like Ciming Physical Examination and Aoya International Medical Club. It runs 50 centers in 20 cities serving millions annually. |
| HQ Country | |
| HQ City | Beijing |
| Deal Date | 14 Jun 2017 |
| Valuation | $7M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Meinian Onehealth acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Meinian Onehealth
Meinian Onehealth has invested in 5 companies to date.
Latest investment by Meinian Onehealth was on June 29th 2020. Meinian Onehealth invested in CapitalBio Technology in their $113M Series C round (EV/Revenue multiple available to Pro users).
Latest Investments by Meinian Onehealth
| Description | CapitalBio Technology is a life sciences company commercializing microarray and microfluidic technologies for research, diagnostics, and biosafety. Beijing-headquartered in the Economic-Technological Development Area since 2012, it operates as a core subsidiary of CapitalBio Corporation and the Biological Chip Beijing National Engineering Research Center. The firm supplies chips, instruments, reagents, and software to biomedical researchers and healthcare professionals worldwide. | Zhangshang Tangyi is a health management platform in China focused on diabetes care. Hangzhou-based and founded in 2014, it allows patients to upload glucose readings via apps, receiving doctor guidance. The platform connects 100,000 users with 5,000 physicians across Zhejiang province. | Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services. | SHENZHEN OASIS HEALTH MANAGEMENT is a Shenzhen-based clinic offering internal medicine, surgery, otolaryngology, stomatology, liver and renal function tests, blood routines, color Doppler ultrasounds, cancer screenings, MRI, CT scans, capsule gastroscopy. Services extend to genetic testing, chronic disease management, telemedicine, women's health, corporate wellness via szaoya.com. | |
| HQ Country | |||||
| HQ City | Beijing | Hangzhou | - | Shenzhen | |
| Deal Date | 29 Jun 2020 | 7 Jan 2019 | 11 May 2018 | 19 Dec 2017 | |
| Round | Series C | Series C | Undisclosed stage | Series A | |
| Raised | $113M | $100M | $61M | $2M | |
| Investors | Friend Capital; Guangdong Boyi Jianzhu Shejiyuan; Meinian Onehealth; Hongma Investment; Huzhou Jiasi Enterprise Consulting Service Office; Lianxing Capital; Meinian Onehealth; New Alliance Capital; Red Horse Capital; Sinopec Capital; Suzhou Youcai Huiying Investment Center; Tusholdings | China Capital Investment Group; CICC; Meinian Onehealth; IDG Capital; LB Investment; Ping An Ventures; Samsung Ventures; Tasly Pharmaceutical | Meinian Onehealth | Meinian Onehealth; Tianyi Group | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Meinian Onehealth investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Meinian Onehealth
| When was Meinian Onehealth founded? | Meinian Onehealth was founded in 2004. |
| Where is Meinian Onehealth headquartered? | Meinian Onehealth is headquartered in China. |
| How many employees does Meinian Onehealth have? | As of today, Meinian Onehealth has over 2K employees. |
| Is Meinian Onehealth publicly listed? | Yes, Meinian Onehealth is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Meinian Onehealth? | Meinian Onehealth trades under 002044 ticker. |
| When did Meinian Onehealth go public? | Meinian Onehealth went public in 2005. |
| Who are competitors of Meinian Onehealth? | Meinian Onehealth main competitors include Global Health, Concentra Group, Option Care Health, Medicover, Krishna Institute, Asker Healthcare Group, Mouwasat, LifeStance Health, Kpj Healthcare, IKS Health. |
| What is the current market cap of Meinian Onehealth? | Meinian Onehealth's current market cap is $3B. |
| What is the current revenue of Meinian Onehealth? | Meinian Onehealth's last 12 months revenue is $2B. |
| What is the current revenue growth of Meinian Onehealth? | Meinian Onehealth revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Meinian Onehealth? | Current revenue multiple of Meinian Onehealth is 2.4x. |
| What is the current EBITDA of Meinian Onehealth? | Meinian Onehealth's last 12 months EBITDA is $286M. |
| What is Meinian Onehealth's EBITDA margin? | Meinian Onehealth's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Meinian Onehealth? | Current EBITDA multiple of Meinian Onehealth is 13.2x. |
| How many companies Meinian Onehealth has acquired to date? | As of June 2026, Meinian Onehealth has acquired 1 company. |
| What was the largest acquisition by Meinian Onehealth? | $7M acquisition of Ciming Checkup on 14th June 2017 was the largest M&A Meinian Onehealth has done to date. |
| What companies Meinian Onehealth acquired? | Meinian Onehealth acquired Ciming Checkup. |
| In how many companies Meinian Onehealth has invested to date? | As of June 2026, Meinian Onehealth has invested in 5 companies. |
| What was the last Meinian Onehealth investment? | On 29th June 2020 Meinian Onehealth invested in CapitalBio Technology, participating in a $113M Series C round, alongside Friend Capital, Guangdong Boyi Jianzhu Shejiyuan, Hongma Investment, Huzhou Jiasi Enterprise Consulting Service Office, Lianxing Capital, New Alliance Capital, Red Horse Capital, Sinopec Capital, Suzhou Youcai Huiying Investment Center, and Tusholdings. |
| In what companies Meinian Onehealth invested in? | Meinian Onehealth invested in CapitalBio Technology, Zhangshang Tangyi, Mega Genomics, Vedeng, and SHENZHEN OASIS HEALTH MANAGEMENT. |
See public comps similar to Meinian Onehealth
Lists including Meinian Onehealth
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
